Why the study?
It was unknown whether specific inhibition of the detrimental CaMKII-δ9 splice variant prevents cardiac ischemia/reperfusion injury and what mechanism underlies this effect.
Does CaMKII-δ9 inhibition prevent cardiac ischemia/reperfusion injury and inflammation in preclinical models?
Does CaMKII-δ9 inhibition prevent cardiac ischemia/reperfusion injury and inflammation in preclinical models?
Answers are grounded in this paper and cite their sources.
Specific inhibition of the CaMKII-δ9 splice variant protects against myocardial ischemia/reperfusion injury and inflammation by suppressing NF-κB signaling.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: